BACKGROUND: PROMISE (PROspective Multicenter Imaging Study for Evaluation of Chest Pain) found that initial use of at least 64-slice multidetector computed tomography angiography (CTA) versus functional diagnostic testing strategies did not improve clinical outcomes in stable symptomatic patients with suspected coronary artery disease (CAD) requiring noninvasive testing. OBJECTIVE: To conduct an economic analysis for PROMISE (a major secondary aim of the study). DESIGN: Prospective economic study from the U.S. perspective. Comparisons were made according to the intention-to-treat principle, and CIs were calculated using bootstrap methods. (ClinicalTrials.gov: NCT01174550). SETTING: 190 U.S. centers. PATIENTS: 9649 U.S. patients enrolled in PROMISE between July 2010 and September 2013. Median follow-up was 25 months. MEASUREMENTS: Technical costs of the initial (outpatient) testing strategy were estimated from Premier Research Database data. Hospital-based costs were estimated using hospital bills and Medicare cost-charge ratios. Physician fees were taken from the Medicare Physician Fee Schedule. Costs were expressed in 2014 U.S. dollars, discounted at 3% annually, and estimated out to 3 years using inverse probability weighting methods. RESULTS: The mean initial testing costs were $174 for exercise electrocardiography; $404 for CTA; $501 to $514 for pharmacologic and exercise stress echocardiography, respectively; and $946 to $1132 for exercise and pharmacologic stress nuclear testing, respectively. Mean costs at 90 days were $2494 for the CTA strategy versus $2240 for the functional strategy (mean difference, $254 [95% CI, -$634 to $906]). The difference was associated with more revascularizations and catheterizations (4.25 per 100 patients) with CTA use. After 90 days, the mean cost difference between the groups out to 3 years remained small. LIMITATION: Cost weights for test strategies were obtained from sources outside PROMISE. CONCLUSION: Computed tomography angiography and functional diagnostic testing strategies in patients with suspected CAD have similar costs through 3 years of follow-up. PRIMARY FUNDING SOURCE: National Heart, Lung, and Blood Institute.
BACKGROUND: PROMISE (PROspective Multicenter Imaging Study for Evaluation of Chest Pain) found that initial use of at least 64-slice multidetector computed tomography angiography (CTA) versus functional diagnostic testing strategies did not improve clinical outcomes in stable symptomatic patients with suspected coronary artery disease (CAD) requiring noninvasive testing. OBJECTIVE: To conduct an economic analysis for PROMISE (a major secondary aim of the study). DESIGN: Prospective economic study from the U.S. perspective. Comparisons were made according to the intention-to-treat principle, and CIs were calculated using bootstrap methods. (ClinicalTrials.gov: NCT01174550). SETTING: 190 U.S. centers. PATIENTS: 9649 U.S. patients enrolled in PROMISE between July 2010 and September 2013. Median follow-up was 25 months. MEASUREMENTS: Technical costs of the initial (outpatient) testing strategy were estimated from Premier Research Database data. Hospital-based costs were estimated using hospital bills and Medicare cost-charge ratios. Physician fees were taken from the Medicare Physician Fee Schedule. Costs were expressed in 2014 U.S. dollars, discounted at 3% annually, and estimated out to 3 years using inverse probability weighting methods. RESULTS: The mean initial testing costs were $174 for exercise electrocardiography; $404 for CTA; $501 to $514 for pharmacologic and exercise stress echocardiography, respectively; and $946 to $1132 for exercise and pharmacologic stress nuclear testing, respectively. Mean costs at 90 days were $2494 for the CTA strategy versus $2240 for the functional strategy (mean difference, $254 [95% CI, -$634 to $906]). The difference was associated with more revascularizations and catheterizations (4.25 per 100 patients) with CTA use. After 90 days, the mean cost difference between the groups out to 3 years remained small. LIMITATION: Cost weights for test strategies were obtained from sources outside PROMISE. CONCLUSION: Computed tomography angiography and functional diagnostic testing strategies in patients with suspected CAD have similar costs through 3 years of follow-up. PRIMARY FUNDING SOURCE: National Heart, Lung, and Blood Institute.
Authors: Louise D Metz; Mary Beattie; Robert Hom; Rita F Redberg; Deborah Grady; Kirsten E Fleischmann Journal: J Am Coll Cardiol Date: 2006-12-29 Impact factor: 24.094
Authors: Stephan D Fihn; Julius M Gardin; Jonathan Abrams; Kathleen Berra; James C Blankenship; Apostolos P Dallas; Pamela S Douglas; Joanne M Foody; Thomas C Gerber; Alan L Hinderliter; Spencer B King; Paul D Kligfield; Harlan M Krumholz; Raymond Y K Kwong; Michael J Lim; Jane A Linderbaum; Michael J Mack; Mark A Munger; Richard L Prager; Joseph F Sabik; Leslee J Shaw; Joanna D Sikkema; Craig R Smith; Sidney C Smith; John A Spertus; Sankey V Williams Journal: J Am Coll Cardiol Date: 2012-11-19 Impact factor: 24.094
Authors: Mark A Hlatky; Bernard De Bruyne; Gianluca Pontone; Manesh R Patel; Bjarne L Norgaard; Robert A Byrne; Nick Curzen; Ian Purcell; Matthias Gutberlet; Gilles Rioufol; Ulrich Hink; Herwig Walter Schuchlenz; Gudrun Feuchtner; Martine Gilard; Daniele Andreini; Jesper M Jensen; Martin Hadamitzky; Alan Wilk; Furong Wang; Campbell Rogers; Pamela S Douglas Journal: J Am Coll Cardiol Date: 2015-10-14 Impact factor: 24.094
Authors: Pamela S Douglas; Udo Hoffmann; Manesh R Patel; Daniel B Mark; Hussein R Al-Khalidi; Brendan Cavanaugh; Jason Cole; Rowena J Dolor; Christopher B Fordyce; Megan Huang; Muhammad Akram Khan; Andrzej S Kosinski; Mitchell W Krucoff; Vinay Malhotra; Michael H Picard; James E Udelson; Eric J Velazquez; Eric Yow; Lawton S Cooper; Kerry L Lee Journal: N Engl J Med Date: 2015-03-14 Impact factor: 91.245
Authors: G Mowatt; L Vale; M Brazzelli; R Hernandez; A Murray; N Scott; C Fraser; L McKenzie; H Gemmell; G Hillis; M Metcalfe Journal: Health Technol Assess Date: 2004-07 Impact factor: 4.014
Authors: Benjamin J W Chow; Arun Abraham; George A Wells; Li Chen; Terrence D Ruddy; Yeung Yam; Nayia Govas; Phoebe Diane Galbraith; Carole Dennie; Rob S Beanlands Journal: Circ Cardiovasc Imaging Date: 2009-01 Impact factor: 7.792
Authors: Roberta Green; Valeria Cantoni; Mario Petretta; Wanda Acampa; Mariarosaria Panico; Pietro Buongiorno; Giorgio Punzo; Marco Salvatore; Alberto Cuocolo Journal: J Nucl Cardiol Date: 2017-02-15 Impact factor: 5.952
Authors: Viviany R Taqueti; Sharmila Dorbala; David Wolinsky; Brian Abbott; Gary V Heller; Timothy M Bateman; Jennifer H Mieres; Lawrence M Phillips; Nanette K Wenger; Leslee J Shaw Journal: J Nucl Cardiol Date: 2017-06-05 Impact factor: 5.952
Authors: Gianluca Pontone; Alexia Rossi; Marco Guglielmo; Marc R Dweck; Oliver Gaemperli; Koen Nieman; Francesca Pugliese; Pal Maurovich-Horvat; Alessia Gimelli; Bernard Cosyns; Stephan Achenbach Journal: Eur Heart J Cardiovasc Imaging Date: 2022-02-22 Impact factor: 6.875
Authors: Leslee J Shaw; Ron Blankstein; Jill E Jacobs; Jonathon A Leipsic; Raymond Y Kwong; Viviany R Taqueti; Rob S B Beanlands; Jennifer H Mieres; Scott D Flamm; Thomas C Gerber; John Spertus; Marcelo F Di Carli Journal: Circ Cardiovasc Imaging Date: 2017-12 Impact factor: 7.792
Authors: Khaled M Abdelrahman; Marcus Y Chen; Amit K Dey; Renu Virmani; Aloke V Finn; Ramzi Y Khamis; Andrew D Choi; James K Min; Michelle C Williams; Andrew J Buckler; Charles A Taylor; Campbell Rogers; Habib Samady; Charalambos Antoniades; Leslee J Shaw; Matthew J Budoff; Udo Hoffmann; Ron Blankstein; Jagat Narula; Nehal N Mehta Journal: J Am Coll Cardiol Date: 2020-09-08 Impact factor: 24.094